VCs Must Get Back To Basics And Fund Innovation - MassBio Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Now that the "me too" era is over, venture capitalists should turn back to building innovative biotech companies, panelists at MassBio's annual meeting say.
You may also be interested in...
At PSA, Executives Tout the Benefits of Scale
Even as the biggest pharmaceutical companies get bigger--and predict further consolidation to come--top industry executives advocate outsourcing more R&D.
Financings Of The Fortnight: Follow-On Fever
Does the recent rash of follow-on public offerings mean biotech IPOs are around the corner? Recent financings provide reason to think it's possible.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.